\
&
Contact us
\
&
Contact us
Published on | 2 weeks ago
Programmes Digital, Industry & Space Horizon Europe Digital Europe AI ContinentThe Commission unveiled new features for artificial intelligence (AI) researchers and industry on itsAI-on-Demand platform, including an AI marketplace, an AI development tool that requires minimal coding, as well as secure solutions for generative AI and large language models.
The platform, developed jointly by the EU-funded projects AI4Europe and DeployAI, offers trustworthy AI tools and solutions to both researchers and industry. Innovators will find a researcher-focused suite of datasets, tools, and computing resources. SMEs, businesses and public sector organisations will be able to access trusted tools, resources and ready-to-use AI modules tailored for industry needs.
The central access point to a common AI toolbox, is meant to boost the European Union's capabilities, as set out in the AI Continent Action Plan. The Commission invites AI developers to register their tools and solutions, gaining visibility across a growing network of AI innovators, as well as direct exposure to enterprises seeking ready-to-deploy AI solutions. By compiling trusted AI resources, the platform will accelerate secure and scalable AI adoption across European industries and the public sector.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
